

Memo

To: CP-CTNet Colleagues

From: CP-CTNet Steering Committee

Date: January 17, 2025

Subject: Quarterly Steering Committee Information Dissemination

1. NCI Update

- Dr. Szabo noted that a new administration starts next week with the inauguration of the president. The current NCI Director, Kimryn Rathmell, MD, PhD is stepping down. She was sworn in as the 17th NCI director on December 18, 2023. Doug Lowy, MD has been named the acting director. Additionally, today is Monica Bertagnolli, MD's, final day as the NIH director. She has held the position since November 2023. Jay Bhattacharya, MD, PhD, has been nominated as the new director of the NIH.

2. CP-CTNet Business

- Dr. Szabo reminded the LAO PIs of the process of working with NCI contractors (e.g. MRI Global, CCSA). LAOs should not reach out to the contractors directly to ask them to perform work (e.g., source trial agents, etc.). Communications should first be sent to the medical/scientific monitors on the appropriate studies as well as the nurse consultants, who will work with the appropriate Contracting Officer's Representative (COR) to request services. Only authorized NCI staff (the COR for each contract) may request CP-CTNet work from DCP's contractors.
- There were no updates on the submitted grants. Scores likely will be available at the end of February or early March after the grants are reviewed. Summary Statements are anticipated to come out at the end of March or in early April.

3. DMACC Update

- Dr. Kim and Sue Siminski provided updates on the DMACC Data Management and Reporting Unit, Clinical Trials Auditing Unit, and the

Administrative and Logistical Coordination Unit as well as future network statistical initiatives.

4. CP-CTNet Committee Updates

- **EDI Committee Update**
 - **The full committee is on hiatus until the new program is renewed. Meetings will start back up in the fall. The most recent Webinar was very well received.**

5. Cross-Network Trial Updates

- **INT21-05-01 Tri-Ad5 and N-803 Vaccines for Lynch Syndrome**
 - **Dr. Vilar-Sanchez noted that the trial is progressing well and enrollment has been strong. More sites are in the process of being added. There have been no safety concerns. Trial accrual completion is anticipated in the Summer of 2025.**
- **The INT22-09-01 Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer**
 - **Dr. Parnes shared with the group that Janssen withdrew funding support. The trial team has pivoted and will now be using bicalutamide instead of apalutamide. Dr. Messing has quickly revised the protocol. A start date is anticipated in the Spring of 2025.**
- **INT23-14-01 Refining Tamoxifen Dose for Premenopausal Breast Cancer Prevention (RENAISSANCE): A Phase II Single Arm Trial**
 - **Dr. Khan provided an update on the trial and indicated that it truly has been a wonderful demonstration of a cross-network trial as all 5 LAOs are contributing/supporting to its success.**

6. New Topics

- **Dr. Khan inquired about Consortia final reports and their due date and if there were templates. Dr. Szabo said there were no templates and that reports should be concise. Don Johnsey will extract the required information from the Task Orders and send it to the LAOs.**
- **Dr. Khan asked when the I-SCORE meeting agenda might be available so LAOs can move forward with booking travel for speakers and staff. Drs. Szabo and Thompson indicated that**

we should know more hopefully next week after the planning committee meets to discuss the agenda.

7. Concept Solicitation Cycles #22-25

Cycle #	Steering Committee Date	Concept Solicitation Date	Concept Due Date
22	Jan. 17, 2025	Jan. 24, 2025	Apr. 4, 2025
23	Mar. 27, 2025	Apr. 4, 2025	Jun. 6, 2025
24	Jul. 18, 2025	Jul. 25, 2025	Sep. 26, 2025
25	Oct. 24, 2025	Oct. 31, 2025	Jan. 9, 2026

8. Next Steering Committee Meeting

- **Date: March 27, 2025** (at the I-SCORE meeting)